CytomX Therapeutics (CytomX Therapeutics) Price-to-Operating-Cash-Flow : (As of Apr. 24, 2024)

View and export this data going back to 2015. Start your Free Trial

What is CytomX Therapeutics Price-to-Operating-Cash-Flow?

As of today (2024-04-24), CytomX Therapeutics's share price is $1.63. CytomX Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.73. Hence, CytomX Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for CytomX Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 11 years, CytomX Therapeutics's highest Price-to-Operating-Cash-Flow Ratio was 62.94. The lowest was 3.51. And the median was 5.59.

CTMX's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.92
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

CytomX Therapeutics's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-0.27. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.73.

During the past 11 years, CytomX Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 71.40% per year. The lowest was -281.10% per year. And the median was 17.20% per year.

CytomX Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for CytomX Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytomX Therapeutics Price-to-Operating-Cash-Flow Chart

CytomX Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

57.46

CytomX Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of CytomX Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, CytomX Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytomX Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where CytomX Therapeutics's Price-to-Operating-Cash-Flow falls into.

CytomX Therapeutics Price-to-Operating-Cash-Flow Calculation

CytomX Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	1.63	/	-0.731
	=

CytomX Therapeutics's Share Price of today is $1.63.
CytomX Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.73.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

CytomX Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of CytomX Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

CytomX Therapeutics (CytomX Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytomX Therapeutics Inc (NAS:CTMX) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

6C1:Germany

Address

151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

https://www.cytomx.com

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Executives

Marcia Belvin	officer: SVP, Chief Scientific Officer	C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO CA 94080
Christopher Ogden	officer: SVP, Finance and Accounting	C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Jeffrey B Landau	officer: Chief Financial Officer	C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Lloyd A Rowland	officer: General Counsel	AMYLIN PHARMACEUTICALS INC, 9360 TOWNE CENTRE DR, SAN DIEGO CA 92121
Sean A. Mccarthy	director, officer: President and CEO	343 OYSTER POINT BLVD., SUITE 100, SOUTH SAN FRANCISCO CA 94080
Yu-waye Chu	officer: Chief Medical Officer	FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
Elaine V Jones	director	C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Amy C. Peterson	officer: EVP, Chief Development Officer	C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Carlos Campoy	officer: Chief Financial Officer	11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Alison L. Hannah	officer: Chief Medical Officer	12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Alan Ashworth	director	C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO CA 94080
Bvf I Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104